Ashkenazi Jewish women have a 1-in-40 chance of carrying the BRCA mutation and these BRCA-positive women have an 80 percent lifetime risk of developing breast or ovarian cancer. A study by University of Colorado Cancer Center and Shaarei Zedek Medical Center, Israel presented at the European Society of Human Genetics Annual Meeting 2019 shows the importance of healthy women knowing their BRCA status, even when these women choose not to undergo prophylactic mastectomy: Of 63 Ashkenazi Jewish women unaware of their BRCA+ status at the time of breast cancer diagnosis, and 42 women who were aware they were BRCA+ prior to their breast cancer diagnosis (but had decided against surgical prevention), the women who knew their BRCA+ status were diagnosed with earlier stage breast cancer, needed less chemotherapy, less extensive surgery, and had greater overall 5-year survival (98 percent vs. 74 percent).

“The problem is that genetic screening for BRCA by a saliva
or blood test is not recommended by any medical body or health care
organization in healthy Ashkenazi Jewish women without a strong family history.
Therefore, the way women usually find out they have the BRCA gene is only after
they are diagnosed with breast cancer, at which time we’ve lost the opportunity
to offer surgery that could prevent breast cancer or start high-risk breast
cancer screening at an age young enough to detect cancers earlier,” says Rachel
Rabinovitch, MD, FASTRO, CU Cancer Center investigator and professor in the CU
School of Medicine Department of Radiation Oncology.

The BRCA genes, BRCA1 and BRCA2, are tumor-suppressor genes,
meaning that their function is to identify and correct genetic mistakes that
could lead to cancer. When these genes become disabled by mutation, they can no
longer act against tumors, leading to a much greater chance of developing breast
and ovarian cancers. In the general population, about 1 in 400 women carry BRCA
mutations, which most health experts feel is too rare to recommend the wide use
of screening (which leads insurance companies to not cover the test). However,
for Ashkenazi Jewish women, the risk is ten times higher, leading to calls for
increased screening in this population. The test itself is relatively simple,
checking for three specific mutations and costing less than $200.

“We found that women who knew they were BRCA positive and
chose to keep their breasts were much more likely to be diagnosed with
noninvasive breast cancer, earlier stage invasive breast cancer, and need less
morbid cancer therapy; but most
importantly their survival was better,” Rabinovitch says, suggesting that
results argue for routine BRCA screening in women of Ashkenazi Jewish descent.

“However even among those of us who did the study, we do not
agree on when is the best age for genetic screening,” Rabinovitch says.
“My colleagues who live in Israel suggest it should be done at age 30 (the age at
which significant cancer risk begins), but I think that’s too late.”

The reason has to do with the ability to screen embryos for
BRCA mutations and to choose to implant only the embryos without BRCA mutation.

“Testing at age 30 is useful for the woman – it’s before she
is likely to develop breast or ovarian cancer and so offers her the opportunity
for surgical prevention or increased cancer screening. However, by that age, many women have made the
decision to get pregnant, and you’ve deprived them of the option to undergo
procedures which would prevent passing on the BRCA mutation to their children. While
not all women will choose this, I think they should be given the opportunity to
do so,” Rabinovitch says.

Another challenge with early BRCA testing is the social stigma
in some communities that can be associated with a positive finding. “When do
you share with a partner your BRCA status? Would this impact a partner’s
interest in marriage or having children? These legitimate and important questions
are among the consequences of genetic testing,” Rabinovitch explains.

Overall, Rabinovitch advises Ashkenazi Jewish women (and
men) to be screened for the BRCA mutation “if they are willing to deal with the
consequences of that information.” If not, Rabinovitch points out, “it can result
in a whole lot of anxiety without much benefit.”

Study results add to a growing body of evidence that
Rabinovitch hopes will eventually be used to guide new BRCA screening
recommendations in the United States and Israel for healthy Ashkenazi Jews and
other high-risk populations.